CA
NZ
UK
AU
IND
US
IND clearance represents a foundational regulatory milestone for any clinical-stage biotech company, as it grants formal FDA authorization to begin testing an investigational therapy in human subjects. For Atrium, this clearance marks the transition of ATR 1072 from preclinical development into the clinical testing …
Under the terms of the transaction, Lōkahi securityholders received a combination of common and convertible preferred stock, an arrangement expected to yield approximately 90% fully diluted ownership of the combined company once the preferred shares convert. This ownership structure makes clear that Lōkahi is …
The revised guidance range accompanies preliminary first-half 2026 results that already showed clear signs of deteriorating performance, with first-half revenue of €300.1 million and an adjusted EBITDA loss of €42.7 million for the six-month period. Extrapolating the revised full-year range implies continued challenging conditions …
Geographic atrophy is a progressive, vision-threatening form of age-related macular degeneration for which treatment options remain limited, making Annexon's ANX007 program a closely watched asset within the ophthalmology drug development space. Phase 3 enrollment for the ARCHER-II trial was completed back in July 2025, …
The presentation will specifically highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy. BCVA is a standard clinical measure of vision quality used extensively in ophthalmology trials, and a 15-letter loss …
The AAIC data specifically showed consistent results across multiple prespecified clinical endpoints, a notable finding given that this program had faced a significant setback earlier this year. In May 2026, Ionis disclosed that the CELIA trial's topline readout did not meet its primary endpoint, …
Metastatic castration-resistant prostate cancer represents a challenging treatment setting, as patients in this population have typically progressed despite standard androgen deprivation therapy, creating ongoing need for new combination approaches that can extend disease control. Rinzimetostat's advancement into a Phase 3 combination trial with darolutamide, …
Recurrent pericarditis is a condition characterized by repeated episodes of inflammation of the pericardium, the membrane surrounding the heart, causing significant pain and reduced quality of life for affected patients. Current treatment options for recurrent cases remain limited, making a therapy capable of substantially …
The data specifically showed that when isolating patients who achieved therapeutic trough plasma concentrations of the drug, neflamapimod demonstrated statistically significant slowing of DLB progression, along with durable preservation of basal forebrain volume on MRI over 48 weeks. This kind of concentration-based subgroup analysis …
The preliminary figures showed revenue of €300.1 million for the first half of the year, alongside an adjusted EBITDA loss of €42.7 million. Reporting an EBITDA loss, rather than positive earnings, represents a significant deterioration for a company of Evotec's scale and maturity in …
Please wait processing your request...